Phase 2 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are between 18 and 75 years old at the time of signing consent.
• You have been diagnosed with malignant pleural mesothelioma (in the lining of the lungs) or malignant peritoneal mesothelioma (in the lining of the abdomen), confirmed by a tissue sample, and the disease cannot be fully removed by surgery, has come back, has spread, or has stopped responding to treatment.
• You have already received at least one standard treatment for mesothelioma, or a doctor has determined that standard treatment is not suitable, not tolerated, or you have chosen not to pursue it for reasonable reasons.
• Testing of your tumor has confirmed the presence of specific proteins (called MSLN and FAP) at levels required by the study.
• You have at least one area of disease that can be measured or assessed using appropriate scans.
• You are generally active and able to carry out daily activities with little or no limitation (confirm with trial site for exact scoring).
• Your blood counts, kidney, liver, clotting, heart, and lung function are healthy enough to safely receive the study treatments.
• It is medically safe to deliver the treatment directly into your chest cavity or abdominal cavity, depending on where your disease is located.
• Any side effects from previous cancer treatments have mostly resolved, with only minor exceptions such as hair loss, stable nerve symptoms, or managed hormone replacement.
• Your life expectancy is at least 12 weeks.
• If you are able to become pregnant, you have a negative pregnancy test and agree to use contraception as required by the study.
• You are able to understand and sign the informed consent form.

Who may not be able to join:

• You have active or untreated cancer that has spread to the brain or spinal cord lining, or you have seizures that are not under control.
• You have an active, uncontrolled infection of any kind, including bacterial, fungal, viral, or tuberculosis-related infections, or an active infection in the chest or abdominal cavity, or uncontrolled hepatitis B, hepatitis C, or HIV.
• You have an autoimmune disease that required immune-suppressing medication within 14 days before starting the preparatory treatment, or you are taking more than a low daily dose of steroid medication.
• You have serious heart disease, an irregular heartbeat that is not controlled, unstable chest pain, a recent heart attack, or another heart condition that could make the infusion risky.
• You have severe lung scarring or inflammation, require oxygen on a regular basis, or have another lung condition that would make treatment into the chest cavity unsafe.
• You have a risk of a hole forming in the bowel, an uncontrolled bowel blockage, uncontrolled fluid build-up in the abdomen, or any other abdominal condition that would make treatment into the abdominal cavity unsafe (applies to the abdominal group).
• You have previously received a gene-modified cell therapy targeting the same proteins (MSLN or FAP) within a required time period before the study, or you have active graft-versus-host disease following a prior transplant.
• You need to continue receiving other cancer treatments at the same time as this trial (beyond supportive care allowed by the study).
• You are pregnant or currently breastfeeding.
• You have any medical, mental health, personal, or practical circumstances that, in the study doctor's judgment, could affect your safety, your ability to follow the study plan, or the reliability of the study results.

Important: Always verify eligibility with the trial site directly before applying.